{"title":"How much is enough: 3 versus 6 months of adjuvant therapy for colon cancer","authors":"J. Marshall","doi":"10.2217/CRC-2017-0019","DOIUrl":"https://doi.org/10.2217/CRC-2017-0019","url":null,"abstract":"","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":"6 1","pages":"107-109"},"PeriodicalIF":4.2,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/CRC-2017-0019","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47095309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ren Chongxi, Wang Hongchen, Li Jiangchun, Li Sheng
{"title":"Continuum of care strategy in metastatic colorectal cancer: a review","authors":"Ren Chongxi, Wang Hongchen, Li Jiangchun, Li Sheng","doi":"10.2217/CRC-2017-0009","DOIUrl":"https://doi.org/10.2217/CRC-2017-0009","url":null,"abstract":"","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":"6 1","pages":"95-103"},"PeriodicalIF":4.2,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/CRC-2017-0009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41606504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Colorectal cancer incidence and clinicopathological features in northern Tunisia 2007–2009","authors":"Houyem Khiari, M. Hsairi","doi":"10.2217/CRC-2017-0014","DOIUrl":"https://doi.org/10.2217/CRC-2017-0014","url":null,"abstract":"","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":"6 1","pages":"131-141"},"PeriodicalIF":4.2,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/CRC-2017-0014","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48260898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
D. W. Sheneman, Jack L Finch, W. Messersmith, S. Leong, K. Goodman, S. Davis, W. Thomas Purcell, M. McCarter, C. Gajdos, J. Vogel, S. Eckhardt, Christopher H Lieu
{"title":"The impact of young adult colorectal cancer: incidence and trends in Colorado","authors":"D. W. Sheneman, Jack L Finch, W. Messersmith, S. Leong, K. Goodman, S. Davis, W. Thomas Purcell, M. McCarter, C. Gajdos, J. Vogel, S. Eckhardt, Christopher H Lieu","doi":"10.2217/CRC-2017-0008","DOIUrl":"https://doi.org/10.2217/CRC-2017-0008","url":null,"abstract":"Aim: Far less is known about colorectal cancer (CRC) incidence in individuals under the age of 50. This study examined CRC incidence in order to better understand the changing CRC population. Methods: This study analyzed 39,525 CRC cases from the Colorado Central Cancer Registry from 1992 through 2013. Age-adjusted incidence, observed and relative 5-year survival, and estimated annual percentage change was analyzed. Results: Age-adjusted rates averaging 1.7% per year were observed in the under-50 population, while falling on average 4.3% per year (p < 0.05) in the over-50 population. Average-adjusted incidence rose in males under 50 by 2.7% per year (p < 0.05). Conclusion: The absolute incidence of CRC continues to fall in Colorado, however incidence is rising in individuals under 50, particularly males.","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":"6 1","pages":"49-56"},"PeriodicalIF":4.2,"publicationDate":"2017-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/CRC-2017-0008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43333452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
W. L. Gluck, Julie C. Martin, W. Edenfield, K. Chung, D. Arguello
{"title":"Prolonged response of widely metastatic HER2-positive colon cancer to trastuzumab therapy","authors":"W. L. Gluck, Julie C. Martin, W. Edenfield, K. Chung, D. Arguello","doi":"10.2217/CRC-2017-0006","DOIUrl":"https://doi.org/10.2217/CRC-2017-0006","url":null,"abstract":"","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":"6 1","pages":"57-61"},"PeriodicalIF":4.2,"publicationDate":"2017-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/CRC-2017-0006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42764987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Seyed Mohammad Amin Kormi, Shima Ardehkhani, M. Kerachian
{"title":"New insights into colorectal cancer screening and early detection tests","authors":"Seyed Mohammad Amin Kormi, Shima Ardehkhani, M. Kerachian","doi":"10.2217/CRC-2017-0007","DOIUrl":"https://doi.org/10.2217/CRC-2017-0007","url":null,"abstract":"","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":"6 1","pages":"63-68"},"PeriodicalIF":4.2,"publicationDate":"2017-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/CRC-2017-0007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43537240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
R. Cohen, M. Svrcek, A. Duval, Y. Parc, P. Österlund, T. André
{"title":"Immune checkpoint inhibitors for patients with colorectal cancer: mismatch repair deficiency and perspectives","authors":"R. Cohen, M. Svrcek, A. Duval, Y. Parc, P. Österlund, T. André","doi":"10.2217/CRC-2017-0004","DOIUrl":"https://doi.org/10.2217/CRC-2017-0004","url":null,"abstract":"Harnessing the immune system to fight tumor cells is becoming a promising and innovative therapeutic strategy for a large spectrum of malignancies. The evaluation of immunotherapy in the context of colorectal cancers (CRCs) has brought to light mismatch repair deficiency as a major predictive biomarker for the efficacy of immune checkpoint blockade. In this review, we summarize the promising results of immune checkpoint inhibitors for patients with metastatic CRCs harboring mismatch repair deficiency, with special emphasis on further clinical development. Given the biological determinants of sensitivity to immune checkpoint blockade, we will also elucidate points that could unlock the potential of immunotherapy for patients with mismatch repair-proficient CRC.","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":"6 1","pages":"23-31"},"PeriodicalIF":4.2,"publicationDate":"2017-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/CRC-2017-0004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41329789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
K. Harada, D. Kaya, Shumei Song, H. Baba, J. Ajani
{"title":"Genomic profiling of colorectal cancers and the future of personalized treatment","authors":"K. Harada, D. Kaya, Shumei Song, H. Baba, J. Ajani","doi":"10.2217/CRC-2016-0017","DOIUrl":"https://doi.org/10.2217/CRC-2016-0017","url":null,"abstract":"New technologies have enabled faster, cheaper and more accurate genomic and other types of profiling. Therefore, treatment has become more customized according to molecular subtype. Here, we summarize the current status of genomic profiling for colorectal cancer (CRC) and discuss future directions. Recently, the CRC Subtyping Consortium classified CRC into four subtypes: CMS1, microsatellite instability immune (14%); CMS2, canonical (37%); CMS3, metabolic (13%); and CMS4, mesenchymal (23%). Testing for KRAS, NRAS and BRAF mutations, and microsatellite instability status in CRC has proven essential for treatment decisions. Tumor heterogeneity and the evolution of drug-resistant subclones after therapy should be further assessed and pursued. Patient-derived xenografts and liquid biopsies might facilitate the development of optimum and accurate personalized therapy regimens.","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":"6 1","pages":"11-22"},"PeriodicalIF":4.2,"publicationDate":"2017-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/CRC-2016-0017","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42731058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Lapeyre-Prost, M. Terme, S. Pernot, E. Marcheteau, Anne-Laure Pointet, T. Voron, E. Tartour, J. Taieb
{"title":"Immune therapy in colorectal cancer","authors":"A. Lapeyre-Prost, M. Terme, S. Pernot, E. Marcheteau, Anne-Laure Pointet, T. Voron, E. Tartour, J. Taieb","doi":"10.2217/CRC-2017-0002","DOIUrl":"https://doi.org/10.2217/CRC-2017-0002","url":null,"abstract":"The evidence that the immune system, when rightly stimulated, can eradicate cancer cells, combined with the latest knowledge about antitumor immunity, has led to recent progress in cancer immunotherapy. While infiltration of tumors with immune cells is described in advanced stage colorectal cancer (CRC), the first data concerning the clinical efficacy of immune-targeted therapies in CRC patients were disappointing. The evidence of tumor responses in CRC patients with microsatellite instability treated with immune checkpoint blockers has renewed the interest for research in the field of CRC immunotherapy. In this article, we briefly review the role of T lymphocytes infiltrating CRC tumors in order to introduce a brief history of CRC immunotherapy and then current trials involving immune-based strategies and particularly immune checkpoint blockers.","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":"6 1","pages":"1-10"},"PeriodicalIF":4.2,"publicationDate":"2017-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/CRC-2017-0002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45018124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}